FDA approves Jentadueto XR (linagliptin + metformin =extended-release) for type 2 diabetes- Boehringer Ingelheim and Eli Lilly
The FDA has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets, from Boehringer Ingelheim and Eli Lilly, for the treatment of type 2 diabetes (T2D) in adults. The safety and efficacy of Jentadueto XR have been established based on adequate and well-controlled studies of linagliptin and metformin co-administered in patients with T2D inadequately controlled on diet and exercise and in combination with sulfonylurea.
Comment: Jentadueto XR combines 2.5 mg or 5 mg of linagliptin with 1000 mg of metformin. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins